Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHAPE: Elamipretide in Older Adults
NCT07275424Phase 2Recruiting
- Start
- Nov 2025
- Primary completion
- Mar 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of elamipretide in aging. Primary endpoints: Number of participants with treatment-related adverse events at 4 weeks and Number of participants completed 4 weeks of injection. Started Nov 2025; status: recruiting.
02
Drugs
elamipretide
03
Conditions
aging
Beyond the preview
Go deeper on NCT07275424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07275424.